Search Results - "Marone, Valerie"

Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases by Farmer, Luc J, Ledeboer, Mark W, Hoock, Thomas, Arnost, Michael J, Bethiel, Randy S, Bennani, Youssef L, Black, James J, Brummel, Christopher L, Chakilam, Ananthsrinivas, Dorsch, Warren A, Fan, Bin, Cochran, John E, Halas, Summer, Harrington, Edmund M, Hogan, James K, Howe, David, Huang, Hui, Jacobs, Dylan H, Laitinen, Leena M, Liao, Shengkai, Mahajan, Sudipta, Marone, Valerie, Martinez-Botella, Gabriel, McCarthy, Pamela, Messersmith, David, Namchuk, Mark, Oh, Luke, Penney, Marina S, Pierce, Albert C, Raybuck, Scott A, Rugg, Arthur, Salituro, Francesco G, Saxena, Kumkum, Shannon, Dean, Shlyakter, Dina, Swenson, Lora, Tian, Shi-Kai, Town, Christopher, Wang, Jian, Wang, Tiansheng, Wannamaker, M. Woods, Winquist, Raymond J, Zuccola, Harmon J

“…While several therapeutic options exist, the need for more effective, safe, and convenient treatment for a variety of autoimmune diseases persists. Targeting…”
Get full text

Translating slow-binding inhibition kinetics into cellular and in vivo effects by Walkup, Grant K, You, Zhiping, Ross, Philip L, Allen, Eleanor K H, Daryaee, Fereidoon, Hale, Michael R, O'Donnell, John, Ehmann, David E, Schuck, Virna J A, Buurman, Ed T, Choy, Allison L, Hajec, Laurel, Murphy-Benenato, Kerry, Marone, Valerie, Patey, Sara A, Grosser, Lena A, Johnstone, Michele, Walker, Stephen G, Tonge, Peter J, Fisher, Stewart L

“…Drug-target residence time is viewed as a predictor of the clinical efficacy of small-molecule drugs. A pharmacodynamic model, taking into account the target…”
Get full text